Title of Study: A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Fast Facts:
Protocol number:
ML18542
Sponsor:
Roche S.p.A.
Company division:
Pharmaceutical
Product name:
MabThera/Rituxan
Generic name:
rituximab
Phase of development:
III
Therapeutic area, approved indication:
Idiopathic Thrombocytopenic Purpura
Date of report:
To be Published
Clinical study summary: This trial does not yet have clinical trial results posted on this website. All trial results will be posted within one year of approval or one year after trial completion, unless the release of information is restricted due to journal publication timing or pending regulatory filing. For further information on the timing of posting clinical trial results please consult the Roche policy for posting information on this website.
This site is run by CenterWatch, a publishing company that focuses on the clinical Trial Listings industry. The information provided in this service is designed to help patients find clinical Trial Results that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these Trial Listings.
Trial Results updated:
September 29, 2008 at 10:25:47 AM
